Filing Details
- Accession Number:
- 0001181431-10-003562
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2010-01-19 12:00:00
- Reporting Period:
- 2010-01-14
- Filing Date:
- 2010-01-19
- Accepted Time:
- 2010-01-19 18:19:36
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1138412 | Genoptix Inc | GXDX | Services-Medical Laboratories (8071) | 330840570 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1414837 | A Douglas Schuling | C/O Genoptix, Inc. 1811 Aston Avenue Carlsbad CA 92008 | Ex Vp And Cfo | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2010-01-14 | 6,631 | $1.24 | 31,638 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2010-01-14 | 951 | $0.38 | 32,589 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2010-01-14 | 7,582 | $35.71 | 25,007 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Employee Stock Option (right to buy) | Disposition | 2010-01-14 | 6,631 | $0.00 | 6,631 | $1.24 |
| Common Stock | Employee Stock Option (right to buy) | Disposition | 2010-01-14 | 951 | $0.00 | 951 | $0.38 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 3,869 | 2016-07-16 | No | 4 | M | Direct | |
| 17,796 | 2013-10-22 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 16, 2009.
- The range of sale prices received is $35.60 to $35.88. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased or sold at each separate price.
- Immediately exercisable.
Billionaire Hedge Funds
